Filtered By:
Specialty: Cardiology
Condition: Heart Failure
Drug: Losartan

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study Clinical Trial
In the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study, 4.8 years’ losartan- versus atenolol-based antihypertensive treatment reduced left ventricular hypertrophy and cardiovascular end points, including cardiovascular death and stroke. However, there was no difference in myocardial infarction (MI), possibly related to greater reduction in myocardial oxygen demand by atenolol-based treatment. Myocardial oxygen demand was assessed indirectly by the left ventricular massxwall stressxheart rate (triple product) in 905 LIFE participants. The triple product was included as time-varying covariate...
Source: Hypertension - October 7, 2015 Category: Cardiology Authors: Devereux, R. B., Bang, C. N., Roman, M. J., Palmieri, V., Boman, K., Gerdts, E., Nieminen, M. S., Papademetriou, V., Wachtell, K., Hille, D. A., Dahlof, B. Tags: Hypertrophy, Other etiology Clinical Trial Source Type: research

Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
Conclusion: In hypertensive patients with ECG left ventricular hypertrophy with existing or new atrial fibrillation, digoxin use is not associated with a significantly increased risk of all-cause mortality after adjusting for other independent predictors of death and for the factors associated with the propensity to use digoxin in this population. These findings suggest that factors other than digoxin use may account for the increased mortality found with digoxin use in some studies. Clinical Trials Registration: http://clinicaltrials.gov/ct/show/NCT00338260?order=1
Source: Journal of Hypertension - June 5, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy Original Articles
Conclusions— Development of new-onset AF identifies hypertensive patients at increased risk of SCD. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260.
Source: Circulation: Arrhythmia and Electrophysiology - April 16, 2013 Category: Cardiology Authors: Okin, P. M., Bang, C. N., Wachtell, K., Hille, D. A., Kjeldsen, S. E., Dahlof, B., Devereux, R. B. Tags: Clinical Studies, Arrhythmias, clinical electrophysiology, drugs, Epidemiology Original Articles Source Type: research